Price Alert: Shares of TELA Bio (TELA) Trade 9.31% Higher at Midday June 23

Equities Staff  |

Shares of TELA Bio Inc (NASDAQ: TELA) climbed 9.31% Thursday.

As of 11:52:16 est, TELA Bio is currently sitting at $7.11 and has risen $0.605 so far today.

TELA Bio has moved 22.02% over the last 30 days and has a YTD change of 49.22% based on the prior day’s close.

The company expects its next earnings on 2022-08-10.

For technical charts, analysis, and more on TELA Bio visit the company profile.

About TELA Bio Inc

TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing patients with advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

To get more information on TELA Bio Inc and to follow the company's latest updates, you can visit the company's profile page here: TELA Bio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content